Pfizer expects its stronger non-COVID business to more than offset lower revenue from COVID-related products, though full-year revenue guidance still indicates a decline. The company plans to achieve $2.7 billion in cost savings through 2029, which could improve operating margins. However, challenges such as patent expirations, pricing pressures, and recurring impairment charges may limit profitability gains. Pfizer's stock trades below its historical and peer medians, showing a technical base near major support, with potential for a bullish breakout if key levels are surpassed.
Pfizer's stock price on Pluang stands at USD 27.80 with a slight 1-day decline of 0.05% as of Oct 09, 2026 18:12 WIB. Despite the cautious optimism in the news about Pfizer's potential for a bullish breakout, the stock remains below its 52-week high of USD 29.02 and above its 52-week low of USD 23.67. The platform shows a strong buying interest with 70% of orders to buy, reflecting active investor engagement amid the company's strategic shifts.
Pfizer's dividend yield has risen above 6%, notably higher than peers, due to a share price decline despite steady dividends. While the company maintains a strong earnings buffer and CEO Albert Bourla has assured the dividend will hold, free cash flo...
Moderna's stock rose 5% following its addition to the NASDAQ 100, driven by automatic fund buying linked to the index inclusion. This marks a shift from its COVID-19 vaccine identity to a growth biotech with a promising oncology pipeline, highlighted...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Four well-known companies—Pfizer, UPS, Kraft Heinz, and Ford—offer dividend yields above 5%, but their earnings, cash flow, and debt levels raise doubts about the sustainability of these payouts. Pfizer and UPS pay dividends exceeding their GAAP earn...
Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despi...
